Abstract 14660: The Effect of Sacubitril/Valsartan Therapy on Hospitalization and Mortality in Patients Non-Respondent to Cardiac Resynchronization Therapy

• DOI: 10.1161/circ.148.suppl_1.14660
• Publication Date: 2023-12-19T07:59:21Z
• Authors: Krisztina Maria S...; Anna Zsofia Toth; Vivien Racz; Attila Csaba Nagy; Judit Barta; Attila Borbely; Zoltan Csanadi
• Keywords: Clinical endpoint; Sacubitril, Valsartan

Background: Non-responders to Cardiac Resynchronization Therapy (CRT-NR) have poor prognosis. Sacubitril/valsartan (SV) treatment improved the outcomes of heart failure patients with reduced left ventricular (LV) ejection fraction (HFrEF) in randomized trials; however, limited data are available on specific cohort CRT-NRs. Aim study: We compared hospitalization (HFH) and mortality rates three patient cohorts: CRT-NR S/V versus ACEi/ARB general HFrEF S/V. Methods: 275 HF patients, including 70 CRT-NRs receiving at least for 6 months (Group I); II); 135 without CRT indication therapy III) were included. was defined as a less than 10% improvement (LVEF) after device implantation. Rates HFH composite all-cause mortality/heart transplantation/LVAD mean follow-up 21.5 months. A subgroup analysis also performed (Groups I who demonstrated more increase LVEF (S/V super-responders moderate responders, respectively). Results: similar Groups III (28.5% vs. 28.1%, respectively; p>0.05), while significantly higher (54.2%) Group II (p=0.02). No significant difference endpoint between groups (22.8% 24.2% 22.2%, p=0.08). On treatment, 13 out (18.5%) I) 24 (17.8%) found be SV super-responders. Comparing these 37 168 neither (24.3% vs 30.9%, p=0.07), nor 23.2%, p=0.53) differences. Conclusion: similarly what observed population. benefit this cohort. The extent change not predictive better response or mortality.